CYTK
NASDAQ HealthcareCytokinetics, Incorporated - Common Stock
Biotechnology
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
�� 市场数据
| 价格 | $66.71 |
|---|---|
| 成交量 | 1,464,835 |
| 市值 | 8.22B |
| 贝塔系数 | 0.480 |
| RSI（14日） | 66.4 |
| 200日均线 | $56.25 |
| 50日均线 | $63.99 |
| 52周最高 | $70.98 |
| 52周最低 | $29.31 |
| Forward P/E | -13.41 |
| Price / Book | -12.43 |
🎯 投资策略评分
CYTK 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (69/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🚀 Moon Shot (26/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 CYTK in your text
粘贴任何文章、记录或帖子 — 工具将提取 CYTK 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.